Phase 1 Data Promising for TransCon PTH to Potentially Treat Hypoparathyroidism
TransCon PTH, an investigational therapy for hypoparathyroidism (HP) being developed by Ascendis Pharma, showed positive results in healthy volunteers, according to initial data from a Phase 1 clinical trial. The company presented the trial data recently at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California. “We look forward to…